$APVO
Aptevo Therapeutics Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040983 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.670M $2.716M $3.697M
YoY Change -19.26% -26.54% -10.05%
% of Gross Profit
Research & Development $3.887M $5.462M $3.865M
YoY Change -13.18% 41.32% -18.15%
% of Gross Profit
Depreciation & Amortization $121.0K $150.0K $276.0K
YoY Change -45.5% -45.65% -7.38%
% of Gross Profit
Operating Expenses $3.887M $5.462M $3.865M
YoY Change -13.18% 41.32% -18.15%
Operating Profit -$6.561M -$8.178M -$7.562M
YoY Change -15.71% 8.15% 32.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $227.0K $230.0K -$1.759M
YoY Change -1008.0% -113.08% -24.89%
Pretax Income -$6.330M -$7.948M $27.86M
YoY Change -18.94% -128.53% -445.5%
Income Tax
% Of Pretax Income
Net Earnings -$6.334M -$7.948M $28.01M
YoY Change -17.14% -128.38% -453.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.50 -$1.23 $5.58
Diluted Earnings Per Share -$0.50 -$1.23 $5.58
COMMON SHARES
Basic Shares Outstanding 11.52M 7.290M 5.023M
Diluted Shares Outstanding 12.58M 6.482M 5.023M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.11M $21.01M $29.43M
YoY Change -13.72% -28.63% -51.27%
Cash & Equivalents $19.11M $21.01M $29.43M
Short-Term Investments
Other Short-Term Assets $649.0K $764.0K $768.0K
YoY Change -1.37% -0.52% -66.03%
Inventory
Prepaid Expenses $1.367M $910.0K $655.0K
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $21.13M $22.68M $31.40M
YoY Change -14.18% -27.77% -52.25%
LONG-TERM ASSETS
Property, Plant & Equipment $1.011M $1.134M $1.887M
YoY Change -39.42% -39.9% -61.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $6.003M $6.232M $7.399M
YoY Change -15.18% -15.77% 29.6%
TOTAL ASSETS
Total Short-Term Assets $21.13M $22.68M $31.40M
Total Long-Term Assets $6.003M $6.232M $7.399M
Total Assets $27.13M $28.91M $38.80M
YoY Change -14.41% -25.48% -45.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.000M $4.873M $3.269M
YoY Change 23.34% 49.07% -37.09%
Accrued Expenses $2.225M $1.892M $1.704M
YoY Change -70.62% 11.03% 14.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $2.000M
YoY Change -100.0% -100.0% -81.25%
Total Short-Term Liabilities $6.836M $6.911M $7.003M
YoY Change -12.2% -1.31% -77.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.359M
YoY Change -100.0% -100.0% -45.43%
Other Long-Term Liabilities $5.575M $5.748M $6.390M
YoY Change -10.61% -10.05% -71.48%
Total Long-Term Liabilities $5.575M $5.748M $8.749M
YoY Change 191.88% -34.3% -67.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.836M $6.911M $7.003M
Total Long-Term Liabilities $5.575M $5.748M $8.749M
Total Liabilities $12.41M $12.66M $15.75M
YoY Change -22.11% -19.64% -72.65%
SHAREHOLDERS EQUITY
Retained Earnings -$217.5M -$211.2M -$193.8M
YoY Change 8.02% 9.01% -3.51%
Common Stock $232.3M $227.5M $216.8M
YoY Change 6.96% 4.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.72M $16.25M $23.05M
YoY Change
Total Liabilities & Shareholders Equity $27.13M $28.91M $38.80M
YoY Change -14.41% -25.48% -45.72%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$6.334M -$7.948M $28.01M
YoY Change -17.14% -128.38% -453.13%
Depreciation, Depletion And Amortization $121.0K $150.0K $276.0K
YoY Change -45.5% -45.65% -7.38%
Cash From Operating Activities -$6.237M -$4.803M -$3.070M
YoY Change -9.56% 56.45% -39.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$25.00K
YoY Change -100.0% -100.0% -93.62%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$25.00K
YoY Change -100.0% -100.0% -93.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.342M 481.0K -3.178M
YoY Change -968.4% -115.14% -138.21%
NET CHANGE
Cash From Operating Activities -6.237M -4.803M -3.070M
Cash From Investing Activities 0.000 0.000 -25.00K
Cash From Financing Activities 4.342M 481.0K -3.178M
Net Change In Cash -1.895M -4.322M -6.273M
YoY Change -74.39% -31.1% -318.65%
FREE CASH FLOW
Cash From Operating Activities -$6.237M -$4.803M -$3.070M
Capital Expenditures $0.00 $0.00 -$25.00K
Free Cash Flow -$6.237M -$4.803M -$3.045M
YoY Change -9.5% 57.73% -34.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001671584
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37746
dei Entity Registrant Name
EntityRegistrantName
APTEVO THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1567056
dei Entity Address Address Line1
EntityAddressAddressLine1
2401 4th Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1050
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98121
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
838-0500
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
APVO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11523716
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21006000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22635000
CY2022Q4 apvo Royalty And Milestone Receivable
RoyaltyAndMilestoneReceivable
2500000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
910000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1571000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
764000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
744000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
22680000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27450000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1134000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5098000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5303000
CY2023Q2 us-gaap Assets
Assets
28912000
CY2022Q4 us-gaap Assets
Assets
34215000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4873000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3499000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1292000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2105000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
746000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1102000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6911000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8706000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1456000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5748000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6079000
CY2023Q2 us-gaap Liabilities
Liabilities
12659000
CY2022Q4 us-gaap Liabilities
Liabilities
16241000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7543440
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7543440
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6466294
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6466294
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
49000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227415000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
223962000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211211000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206036000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16253000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17974000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28912000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34215000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3114000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5462000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3865000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9630000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8731000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2716000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3697000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6304000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7556000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8178000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7562000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15934000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13173000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
230000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1759000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
163000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4023000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
9650000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
37182000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
37182000
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7948000
CY2022Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
27861000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6121000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
19986000
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
149000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
946000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
327000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7948000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
28010000
us-gaap Net Income Loss
NetIncomeLoss
-5175000
us-gaap Net Income Loss
NetIncomeLoss
20313000
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.23
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
5.55
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.85
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
4.01
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.23
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
5.55
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.85
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.08
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6482158
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5023321
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7190701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4980625
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6482158
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5023321
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7190701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4980970
us-gaap Profit Loss
ProfitLoss
-5175000
us-gaap Profit Loss
ProfitLoss
20313000
us-gaap Share Based Compensation
ShareBasedCompensation
1380000
us-gaap Share Based Compensation
ShareBasedCompensation
1086000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
328000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
518000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
10000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
3290000
apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-2500000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-3664000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-641000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1248000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
205000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
444000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
205000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2245000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
331000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
-677000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-237000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8187000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3467000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11267000
apvo Repayments Under Liability Related To Sale Of Royalties
RepaymentsUnderLiabilityRelatedToSaleOfRoyalties
6779000
apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
8000
apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
4000
apvo Proceeds From Milestones Related To Sale Of Royalties
ProceedsFromMilestonesRelatedToSaleOfRoyalties
10000000
apvo Transaction Costs For Milestones Related To Sale Of Royalties
TransactionCostsForMilestonesRelatedToSaleOfRoyalties
500000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2083000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
436000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1392000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8114000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1629000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16326000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22635000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46303000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21006000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29977000
apvo Change In Rou Asset And Lease Liability From Lease Remeasurement
ChangeInROUAssetAndLeaseLiabilityFromLeaseRemeasurement
4372000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17974000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-8000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1602000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
915000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
2773000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
23256000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-2000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
482000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
465000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7948000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16253000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1216000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-4000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
601000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7697000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5884000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
436000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
485000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
28010000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23047000
CY2023Q2 apvo Number Of Technology Platforms
NumberOfTechnologyPlatforms
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the unaudited condensed financial statements and accompanying notes. Estimates are used for, but not limited to, clinical accruals, useful lives of equipment, commitments and contingencies, stock-based compensation, and incremental borrowing rate (IBR) used for our lease. Given the global economic and geopolitical climate, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</span></p>
apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
47500000
CY2023Q2 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000
apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
12500000
apvo Additional Milestone Payment
AdditionalMilestonePayment
10000000
CY2022Q1 apvo Milestone Payment
MilestonePayment
10000000
CY2022Q2 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37200000
CY2023Q1 apvo Milestone Payment
MilestonePayment
2500000
apvo Additional Milestone Payment
AdditionalMilestonePayment
10000000
CY2022Q2 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
149000
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
523000
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
327000
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
149000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
946000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
327000
apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
1500000
apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
300000
apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
CY2023Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
17000000.0
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21600000
apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2023Q2 us-gaap Cash
Cash
4034000
CY2022Q4 us-gaap Cash
Cash
1066000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16972000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
21569000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21006000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22635000
CY2020Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000.0
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
0
apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
47500000
CY2023Q2 apvo Closing Payments Received
ClosingPaymentsReceived
35000000
apvo Milestone Payment
MilestonePayment
12500000
apvo Additional Milestone Payment
AdditionalMilestonePayment
10000000
CY2022Q2 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37200000
CY2023Q1 apvo Milestone Payment
MilestonePayment
2500000
apvo Additional Milestone Payment
AdditionalMilestonePayment
10000000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M29D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7948000
CY2022Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
27861000
CY2021Q4 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
31045000
apvo Milestone Payment Received Net Of Transaction Costs
MilestonePaymentReceivedNetOfTransactionCosts
9500000
apvo Non Cash Interest Expense
NonCashInterestExpense
3416000
us-gaap Payments For Royalties
PaymentsForRoyalties
6779000
apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
CY2022Q2 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
0
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4400000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4400000
us-gaap Variable Lease Cost
VariableLeaseCost
200000
us-gaap Variable Lease Cost
VariableLeaseCost
400000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
297000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
319000
us-gaap Operating Lease Cost
OperatingLeaseCost
594000
us-gaap Operating Lease Cost
OperatingLeaseCost
679000
CY2023Q2 us-gaap Lease Cost
LeaseCost
297000
CY2022Q2 us-gaap Lease Cost
LeaseCost
319000
us-gaap Lease Cost
LeaseCost
594000
us-gaap Lease Cost
LeaseCost
679000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5098000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5303000
us-gaap Operating Lease Payments
OperatingLeasePayments
459000
us-gaap Operating Lease Payments
OperatingLeasePayments
547000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5700000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
600000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6400000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
30000.00
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y10M2D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6121000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
19986000
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0
CY2022Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
149000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
946000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
327000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7948000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
28010000
us-gaap Net Income Loss
NetIncomeLoss
-5175000
us-gaap Net Income Loss
NetIncomeLoss
20313000
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.23
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
5.55
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.85
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
4.01
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.23
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
5.55
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.85
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4.01
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.03
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.13
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.07
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.03
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.13
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.07
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.08
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6482158
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5023321
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7190701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4980625
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6482158
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5023321
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7190701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4980970
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
465000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
484000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1380000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1085000
apvo Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0.30
CY2022Q2 apvo Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0.31
apvo Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.43
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11

Files In Submission

Name View Source Status
0000950170-23-040983-index-headers.html Edgar Link pending
0000950170-23-040983-index.html Edgar Link pending
0000950170-23-040983.txt Edgar Link pending
0000950170-23-040983-xbrl.zip Edgar Link pending
apvo-20230630.htm Edgar Link pending
apvo-20230630.xsd Edgar Link pending
apvo-ex31_1.htm Edgar Link pending
apvo-ex31_2.htm Edgar Link pending
apvo-ex32_1.htm Edgar Link pending
apvo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
apvo-20230630_def.xml Edgar Link unprocessable
apvo-20230630_lab.xml Edgar Link unprocessable
apvo-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apvo-20230630_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apvo-20230630_cal.xml Edgar Link unprocessable